Cantor Fitzgerald set a $10.00 price target on Cascadian Therapeutics (NASDAQ:CASC) in a research note published on Friday. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
Other analysts also recently issued reports about the stock. BidaskClub downgraded shares of Cascadian Therapeutics from a strong-buy rating to a buy rating in a report on Wednesday. Zacks Investment Research upgraded shares of Cascadian Therapeutics from a hold rating to a buy rating and set a $4.50 target price on the stock in a research report on Monday, November 13th. Raymond James Financial cut shares of Cascadian Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, January 31st. Finally, ValuEngine upgraded shares of Cascadian Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday, January 31st. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $7.13.
Cascadian Therapeutics (NASDAQ:CASC) remained flat at $$10.02 during midday trading on Friday. The company’s stock had a trading volume of 2,000 shares, compared to its average volume of 587,267. Cascadian Therapeutics has a one year low of $3.18 and a one year high of $10.21. The company has a market capitalization of $554.28, a P/E ratio of -7.42 and a beta of 3.80.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.